Capitol Street offers timely, in-depth analyses and insight on healthcare policy actions and trends that impact the pharmaceutical, biotech and biosimilar industries, such as formulary, prior authorization, corporate tax, trade, patent and rebate policies. We identify complex or often overlooked effects of policies and decisions on biopharma stakeholders. We also synthesize inputs from a broad set of healthcare sectors that impact biopharma, including PBMs, diagnostic tests, health plans and hospitals.
For example, our clients use Capitol Street to piece together Medicare Part B and Part D reform and to understand how non-government organizations like ICER are changing the conversations in the marketplace. Our clients are informed of policy actions — as they happen and with clear analysis of the impact and ripple-effect.